All In Biotech

Drug Trial Radar · NCT03997383

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Sep 4, 2019

Primary completion

Jun 20, 2022

Study completion Dec 24, 2025

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jun 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.

Conditions

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Interventions

  • PlaceboDrug

    Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.

  • PatisiranDrug

    Patisiran will be administered by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT)Time frame: Baseline, Month 12

Locations

90 sites in 22 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Skokie, Illinois

  • Clinical Trial Site

    Iowa City, Iowa

  • Clinical Trial Site

    Kansas City, Kansas

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Burlington, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Norfolk, Virginia

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Córdoba, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    San Juan Bautista, Argentina

  • Clinical Trial Site

    Santa Fe, Argentina

  • Clinical Trial Site

    Box Hill, Australia

  • Clinical Trial Site

    Westmead, Australia

  • Clinical Trial Site

    Woolloongabba, Australia

  • Clinical Trial Site

    Aalst, Belgium

  • Clinical Trial Site

    Hasselt, Belgium

  • Clinical Trial Site

    Liège, Belgium

  • Clinical Trial Site

    Roeselare, Belgium

  • Clinical Trial Site

    Porto Alegre, Brazil

  • Clinical Trial Site

    Ribeirão Preto, Brazil

  • Clinical Trial Site

    Ribeirão Preto, Brazil

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    São Paulo, Brazil

  • Clinical Trial Site

    São Paulo, Brazil

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.